Lung Cancer Surgery in Australia Trends and Forecast
The future of the lung cancer surgery market in Australia looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets. The global lung cancer surgery market is expected to reach an estimated $5.7 billion by 2031 with a CAGR of 3.4% from 2025 to 2031. The lung cancer surgery market in Australia is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.
• Lucintel forecasts that, within the product type category, surgical device is expected to witness the highest growth over the forecast period.
• Within the end use category, ambulatory surgical center is expected to witness the highest growth over the forecast period.
Emerging Trends in the Lung Cancer Surgery Market in Australia
Australia’s lung cancer surgery landscape is rapidly evolving, driven by its planned national screening rollout and increased adoption of minimally invasive technologies. High urban centers like Sydney, Melbourne, and Brisbane are leading with robotic and VATS procedures. Hospitals are integrating AI and AR tools for surgical planning, enhancing precision and safety. Enhanced Recovery After Surgery (ERAS) protocols and outpatient models are also gaining ground, reducing hospital stays and costs. These emerging trends signal a paradigm shift toward minimally invasive, tech-enabled, and efficient lung cancer care tailored to improve outcomes and resource utilization.
• Expansion of VATS Adoption Nationwide: Australia has seen a major shift from conventional thoracotomy to Video-Assisted Thoracoscopic Surgery (VATS). Many hospitals now use VATS in over 60–90% of lung cancer surgeries. This trend results in reduced post-operative pain, faster recovery times, and shorter hospital stays. Clinical outcomes have improved as institutions implement VATS even for complex resections, demonstrating broader acceptance of this minimally invasive approach across both metropolitan and regional healthcare facilities.
• Growth in Robotic-Assisted Thoracic Surgery (RATS): Robotic-assisted surgery is gaining momentum in Australian thoracic centers, offering enhanced precision and better outcomes. Surgeons benefit from superior instrument articulation and high-definition 3D visualization, allowing safer dissection and improved lymph node retrieval. Robotic lobectomies and segmentectomies are now more accessible beyond major cities, reducing the need for open procedures. Patients experience shorter hospitalizations and lower post-operative complications, establishing robotic thoracic surgery as a growing standard for complex lung cancer treatment.
• Increased Use of Sublobar and Segmental Resections: As detection of early-stage lung cancer improves, segmentectomy and sublobar resections are becoming preferred choices over full lobectomy. These procedures preserve more lung tissue and are especially beneficial for elderly patients or those with comorbidities. Surgeons are increasingly using VATS and robotic platforms to perform these lung-sparing surgeries with precision. The shift supports personalized care, improves post-surgical lung function, and reflects a broader trend toward tailoring treatment to patient needs and tumor characteristics.
• Adoption of ERAS Protocols and Outpatient Care: Enhanced Recovery After Surgery (ERAS) protocols are being implemented widely across Australia’s thoracic units. These standardized pathways reduce complications, encourage early mobilization, and shorten hospital stays. Some hospitals have started offering outpatient lobectomies and same-day discharges for minor resections. This approach not only improves patient satisfaction but also reduces the burden on hospital resources. The combination of ERAS and minimally invasive techniques aligns with Australia’s goal of achieving high-quality, cost-effective cancer care.
• Early Integration of AI/AR and Virtual Planning: Hospitals and research centers are exploring the integration of Artificial Intelligence (AI) and Augmented Reality (AR) into surgical planning and execution. AI assists in analyzing imaging data to guide resection planning, while AR and virtual reality (VR) allow for preoperative simulation and intraoperative navigation. These innovations aim to improve surgical accuracy, reduce operative time, and minimize errors. Though still in pilot phases, these tools signify the future of precision-driven thoracic oncology in Australia.
The lung cancer surgery market in Australia is shifting toward more personalized, less invasive, and technologically advanced care models. Trends like VATS, robotics, segmental resections, ERAS, and AI-assisted planning are redefining surgical workflows and outcomes. As these approaches become mainstream, they are elevating patient care, supporting national screening efforts, and positioning Australia as a leader in modern thoracic surgery.
Recent Developments in the Lung Cancer Surgery Market in Australia
Australia’s healthcare system is rapidly evolving to meet the demands of lung cancer treatment through proactive surgical enhancements. The impending launch of a nationwide screening program is expected to boost early-stage diagnoses, creating greater demand for less invasive surgeries. Alongside this, hospitals are expanding robotic surgery access, implementing ERAS protocols, and introducing new technologies such as VR-based planning. These steps reflect a national commitment to innovation, access, equity, and improved cancer survival rates.
• National Lung Cancer Screening Program Launch: Australia is preparing for the national rollout of a lung cancer screening program, which is expected to detect more cancers at earlier, operable stages. This development is expected to increase the volume of surgical procedures, particularly minimally invasive ones. Hospitals are expanding capacity to accommodate the anticipated rise in early-stage resections, reinforcing the importance of timely access to VATS and robotic-assisted options as part of a comprehensive cancer care model.
• Regional Rollout of Robotic Lobectomy Programs: Robotic-assisted surgery programs, initially limited to major urban hospitals, are now being introduced in regional centers. These expansions have demonstrated excellent clinical outcomes, low complication rates, and enhanced surgical efficiency. The spread of robotic lobectomy programs beyond metropolitan areas improves access to advanced surgical care, enabling patients across Australia to benefit from the latest thoracic techniques without needing to travel long distances.
• ERAS Standardization Across Surgical Centers: Enhanced Recovery After Surgery (ERAS) protocols have become standard across many Australian thoracic surgery departments. These evidence-based protocols streamline perioperative care, reduce hospital stays, and minimize complications. Hospitals are reporting reduced costs and improved patient satisfaction. The widespread adoption of ERAS reflects the country’s shift toward high-efficiency, patient-centered surgical models and ensures that patients undergoing lung cancer surgery receive consistent, quality care nationwide.
• Minimally Invasive Chest Wall Resections: Surgeons are increasingly applying minimally invasive techniques to more complex procedures, such as chest wall resections. Using VATS and robotic platforms, these surgeries offer similar oncological outcomes to traditional open approaches while significantly reducing post-operative pain and recovery time. This capability signals growing expertise within Australian thoracic centers and enhances the country’s reputation for safe, cutting-edge surgical oncology.
• Pilot Studies Using VR for Surgical Assist: Australian hospitals are piloting virtual reality (VR) tools to assist with preoperative planning and simulation. These tools allow surgeons to rehearse complex procedures and optimize instrument placement before entering the operating room. Early results suggest VR may reduce operative times and improve precision. Though still in early development, such technologies indicate the future trajectory of lung cancer surgery in Australia as one rooted in technological advancement and surgical personalization.
Recent developments in Australia’s lung cancer surgery market reflect a holistic upgrade in patient care and system readiness. From national screening to robotic expansions and digital innovation, the country is poised to improve survival rates and patient experiences. These advances are not only transforming surgical protocols but are also paving the way for more accessible and efficient lung cancer care across urban and regional Australia.
Strategic Growth Opportunities for Lung Cancer Surgery Market in Australia
Australia is experiencing notable advances in lung cancer surgery thanks to expanded screening, minimally invasive techniques, and investments in regional healthcare. Early-stage detection is boosting demand for thoracoscopic procedures, while public and private hospitals embrace robotic assistance. Telehealth and perioperative protocols support outpatient care. Collaborations between academic centres and regional providers help disseminate best practices. These trends are creating a diverse surgical landscape that blends cutting-edge technology, community accessibility, and value-based approaches, transforming clinical pathways and patient outcomes across the country.
• Broader Adoption of Video-Assisted Thoracoscopic Surgery (VATS): Australia’s public and private hospitals are prioritising video-assisted thoracoscopic surgery due to smaller incisions, fewer complications, shorter stays, and reduced recovery times. As early detection continues growing, demand for segmentectomies and lobectomies via VATS increases. Implementation of state-level VATS programs supports equitable access beyond major cities. Medical technology vendors offering high-resolution imaging equipment and reusable thoracoscopic instruments tailored to local theatre setups are well-positioned to benefit from the government push toward less invasive surgical options.
• Increasing Use of Robotic-Assisted Thoracic Surgery (RATS): Robotic platforms are being adopted in tertiary cancer centres to enhance surgical precision, especially for complex resections. Surgeons report improved ergonomics and better access to challenging anatomical regions. With ongoing training programs now in place, use of RATS is expanding beyond major cities. Providers that offer integrated support, training partnerships, and tailored financing are well-suited to meet this opportunity. As reimbursement models evolve to support advanced surgical platforms, robotic adoption is expected to spread into more centres.
• Expansion of Ambulatory Surgery for Early-Stage Resections: Ambulatory surgical delivery is gaining momentum in Australia, with select early-stage lung resections moving out of inpatient settings. This shift reflects national goals to reduce hospital occupancy and costs. ASCs are investing in perioperative pathways and equipment tailored for day procedures. Vendors offering modular tools and streamlined service packages that support rapid patient turnover and remote monitoring are primed to capitalise on this transformation.
• Adoption of AI‐Based Imaging and Surgical Planning: Artificial intelligence is increasingly used in preoperative lesion detection and resection mapping. AI platforms integrated with CT imaging assist surgeons in tailoring segmental resections. These tools support consistent surgical planning and enable better patient communication. Australia’s clinical research networks are generating validation data. Developers offering certified AI solutions that integrate with local health records and theatre systems are positioned to shape tomorrow’s surgical workflow.
• Remote Postoperative Care Through Telehealth Platforms: Telehealth is being deployed to support postoperative monitoring, especially for patients in remote areas. Virtual check‑ins, symptom tracking, and community nurse coordination are reducing unnecessary hospital visits and enabling early intervention. Digital platforms integrated with surgical teams and EHRs support protocol adherence and reduce readmission rates. Companies offering secure, easy-to-use postoperative interfaces that comply with Australian health standards can help facilitate this expanding element of surgical care.
Australia’s lung cancer surgery market is evolving with minimally invasive techniques, robotics, day‑surgery models, AI planning tools, and virtual recovery support. These opportunities are decentralising care, optimising clinical efficiency, and enhancing patient engagement. Providers and innovators aligned with these pathways are set to lead during this shift toward accessible and value-driven surgical solutions.
Lung Cancer Surgery Market in Australia Driver and Challenges
Australia’s lung cancer surgery market is currently influenced by advances in early detection, government funding for modernisation, and technological innovation. Drivers include expanded screening, investment in surgical platforms, and streamlined outpatient pathways. However, challenges persist around funding allocation, rural surgeon shortages, and approval timelines for advanced technologies. Addressing these economic, regulatory, and workforce issues will be key to maximising value and ensuring consistent, high-quality care nationwide.
The factors responsible for driving the lung cancer surgery market in Australia include:
• Expansion of Low‑Dose CT Screening Programs: National health initiatives are increasing CT screening for high-risk groups, raising rates of early-stage lung cancers detected. This drives demand for surgical treatment options such as segmentectomy and lobectomy. With rising case volumes, hospitals upgrade surgical capabilities and invest in more advanced equipment. This translates to stable procurement pipelines for both thoracoscopic and robotic platforms and aligns with national goals of early intervention.
• Government Investment in Surgical Modernisation: State and Commonwealth governments are funding initiatives to modernise theatre infrastructure, subsidise equipment, and support workforce training. Grants now support adoption of robotic systems in regional hospitals. This public support underpins transition to minimally invasive surgery models. Manufacturers that can link equipment to health outcomes and cost efficiencies may secure partnerships backed by government investment in regional expansion.
• Shift Toward Ambulatory Surgical Models: Health policy reforms aimed at cost‑savings and shorter hospital stays are encouraging upfront investment in ambulatory surgery. Lung cancer centres are piloting outpatient resections with close remote follow-up. This aligns with the government‘s emphasis on day procedures. Vendors developing equipment kits and perioperative care models for ASCs will find new markets underserved by hospital-centred suppliers.
• Rapid Technological Advances in Surgical Tools: Australia’s research institutions and hospitals are early adopters of new surgical technology. Integration of high-spec imaging, AI tools, and robotics is accelerating. Institutions contributing data to validation studies close adoption gaps. Companies that partner on local research, provide training hubs, and support evidence development will be poised for success as Australian providers adopt next-generation systems.
• Telehealth Expansion in Postoperative Pathways: Investment in nationwide telehealth has accelerated after the pandemic. Hospitals now expect virtual care solutions for discharge planning and recovery. This trend supports remote patient monitoring, reducing readmission and supporting rural populations. Tech providers with secure, interoperable platforms aligned with national digital health architecture can play a key role in future postoperative protocols.
Challenges in the lung cancer surgery market in Australia are:
• High Capital and Operating Costs: Robotic systems and advanced imaging equipment carry significant capital costs. Ongoing maintenance and consumables further strain regional hospital budgets. Budget constraints may delay adoption in smaller centres. Flexible purchasing, subsidies, leasing models, and shared regional consortiums may help overcome these obstacles and ensure broader access.
• Workforce Shortages in Thoracic Specialists: Rural and regional areas face a shortage of specialist thoracic surgeons and trained theatre teams. This limits access to advanced procedures outside urban centres. National training programs, tele‑mentoring, and task‑sharing may alleviate the bottleneck. Until workforce capacity grows, access disparities are likely to persist.
• Regulatory Delays for Innovative Technologies: Approval processes for robotic systems and AI tools remain lengthy, slowing clinical use. Delays in listing newly approved software and devices in public hospital formularies inhibit rapid uptake. Collaboration between industry, regulators, and hospital networks may be needed to fast‑track innovative solutions and align processes with clinical needs.
Australia’s lung cancer surgery market is supported by screening expansion, public funding, and technology innovation. Yet high costs, workforce gaps, and regulatory delays constrain reach. Addressing these issues through targeted investment, regional training, and faster introductions of validated solutions will enable equitable and sustainable growth. Solutions tailored to these local dynamics are poised to deliver improved surgical outcomes and healthcare value across the country.
List of Lung Cancer Surgery Market in Australia Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, lung cancer surgery companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lung cancer surgery companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Lung Cancer Surgery Market in Australia by Segment
The study includes a forecast for the lung cancer surgery market in Australia by product type, surgery, and end use.
Lung Cancer Surgery Market in Australia by Product Type [Analysis by Value from 2019 to 2031]:
• Surgical Devices
• Endosurgical Equipment
• Monitoring or Visualizing Equipment
Lung Cancer Surgery Market in Australia by Surgery [Analysis by Value from 2019 to 2031]:
• Robotic Surgery
• Thoracotomy
• Video Assisted Surgery
• Percutaneous Surgery
• Endobronchial Surgery
Lung Cancer Surgery Market in Australia by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Specialty Cancer Care Centers
• Ambulatory Surgical Centers
• Others
Features of the Lung Cancer Surgery Market in Australia
Market Size Estimates: Lung cancer surgery in Australia market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Lung cancer surgery in Australia market size by product type, surgery, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different product type, surgery, and end use for the lung cancer surgery in Australia.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lung cancer surgery in Australia.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the lung cancer surgery market in Australia?
Answer: The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.
Q2. What are the major segments for lung cancer surgery market in Australia?
Answer: The future of the lung cancer surgery market in Australia looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets.
Q3. Which lung cancer surgery market segment in Australia will be the largest in future?
Answer: Lucintel forecasts that surgical device is expected to witness the highest growth over the forecast period.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the lung cancer surgery market in Australia by product type (surgical devices, endosurgical equipment, and monitoring or visualizing equipment), surgery (robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery, and endobronchial surgery), and end use (hospitals, specialty cancer care centers, ambulatory surgical centers, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Lung Cancer Surgery Market in Australia, Lung Cancer Surgery Market in Australia Size, Lung Cancer Surgery Market in Australia Growth, Lung Cancer Surgery Market in Australia Analysis, Lung Cancer Surgery Market in Australia Report, Lung Cancer Surgery Market in Australia Share, Lung Cancer Surgery Market in Australia Trends, Lung Cancer Surgery Market in Australia Forecast, Lung Cancer Surgery Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.